Cargando…

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia

BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagberg, Katrina Wilcox, Divan, Hozefa A, Fang, Shona C, Nickel, J Curtis, Jick, Susan S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312705/ https://www.ncbi.nlm.nih.gov/pubmed/28228662 http://dx.doi.org/10.2147/CLEP.S124674

Ejemplares similares

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
por: Ayodele, Olulade, et al.
Publicado: (2021)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments
por: Persson, Rebecca, et al.
Publicado: (2022)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Validation of autism spectrum disorder diagnoses recorded in the Clinical Practice Research Datalink, 1990–2014
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2017)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Prostate sarcomas: A radiological mimic for benign prostatic hyperplasia
por: Whish-Wilson, Thomas, et al.
Publicado: (2020)

Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2018)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Use of 5-Alpha-Reductase Inhibitors Did Not Increase the Risk of Cardiovascular Diseases in Patients with Benign Prostate Hyperplasia: A Five-Year Follow-Up Study
por: Hsieh, Teng-Fu, et al.
Publicado: (2015)

Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men
por: Chang, Jooyoung, et al.
Publicado: (2019)

Maternal depression and antidepressant use during pregnancy and the risk of autism spectrum disorder in offspring
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2018)

Corrigendum: Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2019)

Benign Prostatic Hyperplasia
Publicado: (2015)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia
por: Kim, Su Kang, et al.
Publicado: (2014)

Pharmacologically Treated Anxiety and Depression in People Diagnosed with von Willebrand Disease: Matched Cohort Study
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2023)

Gamma Irradiated Rhodiola sachalinensis Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Downregulating 5-Alpha Reductase and Restoring Testosterone in Rats
por: Xin, Qi, et al.
Publicado: (2019)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Bilateral Atypical Ductal Hyperplasia with Microcalcifications in a Patient with Gynecomastia
por: Vidal, Pedro, et al.
Publicado: (2016)

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
por: Liu, Jiakuan, et al.
Publicado: (2019)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

Aconiti Lateralis Radix Preparata, the Dried Root of Aconitum carmichaelii Debx., Improves Benign Prostatic Hyperplasia via Suppressing 5-Alpha Reductase and Inducing Prostate Cell Apoptosis
por: Park, Jinbong, et al.
Publicado: (2019)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
por: Liu, Zhanliang, et al.
Publicado: (2022)

Role of 5 alpha-reductase inhibitors in the management of prostate cancer
por: Hudak, Steven J, et al.
Publicado: (2006)

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors
por: Foldes, Cara A., et al.
Publicado: (2020)

5-alpha reductase inhibitors use in prostatic disease and beyond
por: Chislett, Bodie, et al.
Publicado: (2023)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t0u4q42im17kso9g76tsi38o05